FPS Inhibitors
1 drugsAbout FPS
Farnesyl pyrophosphate synthase (FPS) is an enzyme involved in the isoprenoid biosynthesis pathway, crucial for producing cholesterol, heme A, and isoprenoids required for protein prenylation. Protein prenylation anchors proteins to cell membranes, which is vital for cell signaling and growth.
FPS is a protein target of interest in oncology, though direct genetic evidence linking FPS to specific diseases is currently unavailable. Modulating FPS activity may offer therapeutic benefits in cancer by disrupting cell signaling and growth.
LORBRENA (Pfizer) is the only FDA-approved drug targeting FPS, with a small molecule modality. FPS has a single approved drug in oncology, highlighting the potential for further drug development.
Top FPS Drugs
Pfizer is the only company with an approved drug targeting FPS.
The lack of competitors indicates a high-risk, high-reward opportunity for companies willing to invest.
FPS Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets FPS, using small molecule modality.
Exploring other modalities like antibodies or PROTACs could expand the therapeutic potential of FPS inhibition.
FPS Clinical Trials 36 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on FPS. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 12 | 6 | 3 | 3 | 67% |
| Phase 2 | 16 | 3 | 3 | 10 | 50% |
| Phase 3 | 3 | 0 | 0 | 3 | - |
| Phase 4 | 5 | 2 | 0 | 3 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
FPS Drug Approval Timeline (2018 - 2018)
LORBRENA was first approved in 2018 and remains the only approved FPS-targeting drug.
The absence of recent approvals suggests either limited interest or challenges in developing FPS inhibitors.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 23 (5 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on FPS. A trial counts if an approved drug acting on FPS is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.